Data from the UK’s National Health Service EndoBarrier Service show a significant reduction in HbA1c, weight, liver fat, and cardiovascular disease risks as well as a reduction in the need for insulin in some patients.
The Cupertino, CA-based company released preliminary data from the Apple Heart Study, which demonstrates the effectiveness of wearables to detect atrial fibrillation.
The Abbott Park, IL-based company’s expanded indication would allow the MitraClip to address the secondary form of mitral regurgitation and would significantly increase the amount of people with MR able to be treated by the device.
The Kalamazoo, MI-based company is expected to pay $110 million up front, plus an additional $110 million in milestones to pick up OrthoSpace.
Watchman has been a significant driver for Boston Scientific and is expected to have strong growth this year as well.
Norman Sharpless, director of the National Cancer Institute, will become “acting” commissioner of FDA after commissioner Scott Gottlieb abruptly announced he is leaving the position.
As the Irvine, CA-based company strengthens its mitral valve portfolio, it also faces a lawsuit from Abbott Laboratories over the Pascal system.
The agency released a letter to healthcare providers pointing out the risks and said it would hold a public advisory committee meeting.
Ablative Solutions revealed data from the Peregrine Post-Market Study during the 2019 Cardiovascular Research Technologies meeting in Washington D.C. recently.
A successor has not yet been named and it is expected that Gottlieb will leave the position sometime next month.